CLINICAL TRIALS PROFILE FOR FASLODEX
✉ Email this page to a colleague
505(b)(2) Clinical Trials for faslodex
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Dosage | NCT00099437 ↗ | Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. | Active, not recruiting | AstraZeneca | Phase 3 | 2005-02-08 | The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatment |
| New Dosage | NCT01300351 ↗ | Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women | Completed | AstraZeneca | Phase 3 | 2011-03-01 | The purpose of this study is to evaluate the efficacy of a new dose of 500mg Fulvestrant with the standard dose of 250mg in Chinese postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed a prior endocrine treatment. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for faslodex
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00006903 ↗ | Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer | Unknown status | AstraZeneca | Phase 2 | 2004-08-30 | This phase II trial is studying fulvestrant to see how well it works in treating patients with recurrent, persistent, or metastatic endometrial cancer. Estrogen can stimulate the growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells. |
| NCT00006903 ↗ | Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer | Unknown status | National Cancer Institute (NCI) | Phase 2 | 2004-08-30 | This phase II trial is studying fulvestrant to see how well it works in treating patients with recurrent, persistent, or metastatic endometrial cancer. Estrogen can stimulate the growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells. |
| NCT00006903 ↗ | Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer | Unknown status | Gynecologic Oncology Group | Phase 2 | 2004-08-30 | This phase II trial is studying fulvestrant to see how well it works in treating patients with recurrent, persistent, or metastatic endometrial cancer. Estrogen can stimulate the growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells. |
| NCT00010153 ↗ | ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer | Terminated | Breast International Group | Phase 3 | 2000-11-01 | RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ICI 182780 before surgery may block the uptake of estrogen by the tumor cells and prevent metastases. It is not yet known if ICI 182780 is effective in preventing breast cancer metastases. PURPOSE: Randomized phase III trial to study the effectiveness of ICI 182780 given before surgery in treating women who have stage I or stage II primary breast cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for faslodex
Condition Name
Clinical Trial Locations for faslodex
Trials by Country
Clinical Trial Progress for faslodex
Clinical Trial Phase
Clinical Trial Sponsors for faslodex
Sponsor Name
